Wikipedia -WSS

Wikipedia

author：focus 2025-09-29 00:39:01 - browse：4177

The headquarter of Biotechnology company Ionis Pharmaceuticals, consists of glass windows, pale yellow exteriors and plants outside the building — biotech coverage from STAT — courtesy Ionis Pharmaceuticals

Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of late-stage trials showed that its experimental therapy for hereditary angioedema benefitted patients — including those taking drugs currently on the market.

In one of the Phase 3 trials, dubbed OASIS, patients with hereditary angioedema, a rare disease characterized by severe bouts of swelling, were given injections of donidalorsen either monthly or every two months. Those in the former group had an 81% lower monthly rate of swelling attacks after 25 weeks than patients given a placebo, while the reduction compared to placebo was 55% for those treated every two months.

The other study, OASISplus, found that donidalorsen’s benefits deepened and converged after up to an additional year of treatment, with swelling attack rates dropping by 92% to 93% regardless of how often patients were dosed. Notably, this study also tracked patients who switched over to donidalorsen from existing therapies meant to prevent swelling attacks, including drugs sold by Takeda and BioCryst Pharmaceuticals. Patients who switched to the Ionis drug saw their swelling attack rates drop by 62% compared to previous treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： How state and local governments are sidelining science

WSS

How state and local governments are sidelining science

How state and local governments are sidelining science

Type 2 diabetes prevention programs work at large scale: study

Ukrainian soldiers say they owe lives to US

Ventyx halts psoriasis drug development after lackluster trial results

Weight loss drugs should be covered by insurers, AMA says

entertainment

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Affirmative action in medical school literally saved lives

UnitedHealth wins $3.3 billion takeover of Amedisys

The cancer drug shortage isn’t new — and neither are the solutions

Type 2 diabetes prevention programs work at large scale: study

Affirmative action in medical school literally saved lives

Brazil's Jair Bolsonaro is barred from running for office until 2030

New air purifier tech could be key to improving indoor air quality

White House drug czar issues call for 'recovery

George Santos makes 1st court appearance after pleading not guilty to 13 counts

ADA: All diabetes patients should be screened for liver condition

hotspot

Medical experts exlpore how to eliminate bias in clinical algorithms

Healthy food access boosts outcomes in two studies

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

FDA reorg will put new emphasis on investigations, sources say

Publishing genetic code of viruses could cause disaster

entertainment

hotspot

knowledge

focus